Sanquin Health Solutions

We are proud to announce that our Monocyte Activation Test (MAT) expert Marijke Molenaar- de Backer is invited to speak at a meeting funded by Bill & Melinda Gates Foundation. Marijke will discuss how to implement MAT for biologics at The Animal-Free Safety Assessment (AFSA) Collaboration workshop. https://lnkd.in/gsdJgEau Marijke will provide insights into the use of different MAT formats in testing human albumin preparations. She will also demonstrate how the MAT can be used for testing outer membrane vesicle (OMV) vaccines. This adaptation had some challenges, as OMV vaccines typically already activate the monocytes by themselves. #MAT #MonocyteActivationTest #vaccines Sanquin Annick de Vries

How to assess immunogenicity? The latest insights advise a fit-for-purpose approach where immunogenicity assessment is considered as a biomarker. Above all: immunogenicity testing should provide informative data, dependent on the context of use. This was the result of the European Bioanalysis Forum (EBF) Focus Workshop, including our principal scientist Karien Bloem, that critically re-evaluated the current paradigm for clinical immunogenicity assessment. Based on 20+ years of accumulating knowledge and experience these findings are published here: https://lnkd.in/eev7Yuug Annick de Vries Floris Loeff #EBF #Bioanalysis #Immunogenicity #SanquinHealthSolutions

Meet my colleagues!

This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "IgG Glycosylation as Sugar Switches" led by Gestur Vidarsson from the Department of Experimental Immunohematology at Sanquin Research, Amsterdam, and the Department of Biomolecular Mass Spectrometry and Proteomics at the Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, stands out. This session will delve into the complex world of IgG glycosylation and its profound impact on antibody function and immune regulation. Attendees will explore how subtle changes in sugar structures attached to IgG can act as switches, modulating the immune system's response to pathogens, vaccines, and autoimmunity. This cutting-edge research opens new avenues for therapeutic interventions, highlighting the importance of glycobiology in immunology. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "IgG Fc Receptors in Platelet Auto- and Alloimmunity" led by Alan H. Lazarus from the Department of Laboratory Medicine and Pathobiology at the University of Toronto, Canada, stands out. This session will delve into the critical role of IgG Fc receptors in destruction of antibody-coated cells and the immune modulation by antibodies. Data obtained in mouse models are currently also tested in in vitro models with human cells and offer a promise to understand antibody-mediated immunomodulation. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

💡 𝗟𝗮𝘀𝘁 𝗰𝗵𝗮𝗻𝗰𝗲 𝘁𝗼 𝘀𝗶𝗴𝗻 𝘂𝗽 𝘄𝗶𝘁𝗵 𝗽𝗿𝗶𝗰𝗲 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲 Planning to join the 𝟭𝟳𝘁𝗵 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗣𝗹𝗮𝘁𝗲𝗹𝗲𝘁 𝗮𝗻𝗱 𝗚𝗿𝗮𝗻𝘂𝗹𝗼𝗰𝘆𝘁𝗲 𝗜𝗺𝗺𝘂𝗻𝗼𝗯𝗶𝗼𝗹𝗼𝗴𝘆 (𝗘𝗦𝗣𝗚𝗜)? Register now and take advantage of the current lower price before it increases on September 1st. This is your chance to save while securing your place in a program that offers in-depth knowledge and insights into Platelet and Granulocyte Immunobiology. Learn more and sign up here: https://lnkd.in/e9Xvvuis

This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "Inherited Platelet Disorders: Which Omics?" led by Maartje van den Biggelaar from the Laboratory of Proteomics at Sanquin, Amsterdam, stands out. This session will show the use of proteomics with to explore bleeding disorders in more detail. The world of plasma proteins and platelet protein profiling is intriguing! This technology can be utilized to unravel the molecular underpinnings of bleeding disorders, aimed to lead to improved diagnostic methods and the development of targeted therapies. Make sure to register before September 1st to take advantage of the lower pricing. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "Tools to Study Megakaryocyte Biology" led by Julia Tilburg from the Department of Molecular Hematology at Sanquin Health Services in Amsterdam, stands out. This session will focus on the innovative tools and methodologies that have revolutionized our understanding of megakaryocyte biology. Attendees will learn about the cutting-edge techniques used to investigate megakaryocyte development, function, and their role in platelet production. This comprehensive overview will equip researchers with the knowledge and tools necessary to push the boundaries of megakaryocyte research further, opening up new possibilities for the treatment of hematological diseases. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "Drug-Induced Neutropenia" led by Brian Curtis from the Platelet and Neutrophil Immunology Laboratory at Versiti Blood Center of Wisconsin in Milwaukee, stands out. This session will delve into the complexities of drug-induced neutropenia, a significant and often challenging condition encountered in clinical practice. Attendees will gain a deeper understanding of the mechanisms behind drug-induced neutropenia, the latest diagnostic approaches, and strategies for management and treatment. This exploration promises to provide valuable insights into mitigating the risks associated with drug therapies and enhancing patient safety. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.

This year, we are proud to host the 17th European Symposium on Platelet and Granulocyte Immunobiology (ESPGi), a premier event for exploring the most recent advancements in thrombocyte and granulocyte research set to take place from 27th to 29th September 2024. Among the diverse topics to be addressed, one of the sessions dedicated to "TTP: The Long and Winding Road Toward Targeted Therapies" led by Jan Voorberg from the Department of Cellular Hemostasis at Sanquin, Amsterdam, stands out. This session will chart the progress and challenges in developing targeted therapies for Thrombotic Thrombocytopenic Purpura (TTP), a rare but life-threatening disorder. Attendees will journey through the evolving landscape of TTP treatment, from the early recognition of its pathology to the latest advances in targeted therapeutic strategies. This comprehensive overview will offer insights into the complexities of TTP management and the future directions of research that aim to improve patient outcomes. For full details on the symposium, including how to register and the entire program lineup, please visit our website at https://lnkd.in/e9Xvvuis.